IGF-1 Controlled Release by Bioelectric Stimulation Provisional Patent Filed by Leonhardt Ventures

Leonhardt Ventures, CerebraCell & BioLeonhardt File Provisional Patent Application For Electrical Stimulation Controlled Release of IGF-1

Key Tool in Regenerating Brains, Hearts, Eyes, Livers, Kidneys, Breasts, Lungs, Pancreas, Skin, Aortas, Heart Valves, Joints, Limbs and Arteries 

Santa Monica, CA and Salt Lake City, Utah , April 1st, 2016 – /PRBuzz- BioLeonhardt MyoStim www.bioleonhardt.com and CerebraCell both founded by Leonhardt Ventures www.leonhardtventures.com a developer, manufacturer and marketer of advanced organ regeneration products has announced the expansion of their intellectual property portfolios. BioLeonhardt MyoStim and CerebraCell are incubating within the Cal-X Stars Business Accelerator, Inc. www.calxstars.com. CerebraCell is dually incuating at the University of Northern California Science and Technology Center (UNC STIC) http://www.uncm.edu/STIC.php. The startups via Leonhardt Ventures have filed a provisional patent application with the U.S. Patent and Trademark Office for invention claims relating to bioelectric stimulation controlled release of IGF-1 a powerful cell, tissue and complete organ regeneration growth factor with a special focus on heart and brain regeneration but with applicability to a wide range of other organs and tissues.

Howard J. Leonhardt the Founder and CEO of Leonhardt Ventures, Cerebracell and BioLeonhardt MyoStim and Dr. Jorge Genovese a collaborative researcher from Buenos Aires, Argentina are co-inventors of this product. Howard Leonhardt previously patented a series of electrical stimulation devices and signals for homing stem cells to targeted tissues and the controlled differentiation when required into contractile muscle, even within scar tissue, starting back starting back in 2000. Dr. Genovese has been conducting electrical stimulation based regeneration research for over twenty years with numerous published peer reviewed papers.